PubMed Health⌕ Search

Biomedical subjects

G Besançon

Publications and source records attributed to G Besançon.

At least 19 recordsLinked to original sources
PubMed1993

[Drugs for stress].

Speaking of "drugs of stress" is difficult because stress is not a so precise concept. Moreover, the target is not simply the correction of physiological responses to a stimulus, but is the treatment of pathologies which are directly related with stress: post-traumatic stress disorders (PTSD) and performance anxiety. Drug treatment of PTSD is not well codified, even if phenelzine and amitriptyline are, at least relatively, effective medicines. Beta-blockers remain today the main drugs for performance anxiety. Studies about the utility of carbamazepine and clonidine in these disorders are few. Experimental works upon the action of tianeptine on hippocampus cells lead to interesting results. The place of benzodiazepines and neuroleptics is still controversial.

Anxiety Disorders↗
PubMed1992

[Clinical study of 5 families with bipolar disorder].

Five pedigrees of bipolar patients with at least two bipolar subjects on two generations have been identified in psychiatric departments of Nantes, Montpellier and Challans for linkage studies. In each pedigree, it was found one or more patients suffering from other conditions, like Borderline personality, Anorexia-bulimia, Mental retardation with dysmorphia, and Panic disorders. Mood disorders spectrum and therapeutic implications are discussed.

Adult↗
PubMed1984

[Not Available].

Explore the source record for details and available documents.

History, Modern 1601-↗
PubMed1983

[Treatment of somatic manifestations of anxiety].

The somatic manifestations of anxiety are to distinguish from distress accompanying from distress accompanying the course of severe somatic diseases; they are evoked as are their peculiar clonical aspects in the neurotic, psychosomatic and psychotic register. The methods of their treatment are recalled in two chapters: the therapeutic means - drug therapy and psychotherapy - and the therapeutic strategy. It always passes by an etiologic approach of anxiety, the elucidation of the sense in the patient's history. The doctor-patient relationship is an important determinant in the treatment.

Anti-Anxiety Agents↗
PubMedDate not supplied

[Blood concentrations of maprotiline in depressive patients].

Blood levels of Maprotiline were analysed and their relationship to the clinical response was examined in 89 depressed inpatients, according DSM III criteria for Major Depressive Episode, given the drug treatment for 3 weeks. Maprotiline produced marked decreases in mean MADRS and COVI scale scores by the end of treatment. On day 21, no correlation between blood levels of Maprotiline and MADRS or COVI scores were found when all patients were considered. Nevertheless, significant correlations were observed on day 14 (r = .22; p less than .05 for MADRS and r = .23; p less than .05 for COVI scale). In addition, a significant correlation between MADRS or COVI scale scores and Maprotiline blood levels were observed on days 14 and 21 in subgroups of young patients, severe depression (high scores to clinical global investigations), during of at least 3 months, treated without other drug than Maprotiline and good responders.

Adult↗
PubMedDate not supplied

[Double-blind study of mianserin and fluoxetine in ambulatory therapy of depressed patients].

A double blind controlled trial was carried out in 65 depressed out-patients to compare the efficacy and tolerance of mianserin with fluoxetine. The two compounds present very different pharmacological activities. Mianserin is an antagonist of the alpha 2-adrenergic receptors, while fluoxetine is an inhibitor of recapture specific to serotonin. Requirements for inclusion were: depressive episode of less than 2 months duration, meeting the criteria for one of the sub-types of depression described in DSM III, with a minimum score of 25 on the Montgomery Asberg Depressive Rating Scale (MADRS). The patient's ages ranged from 18 to 65. The only psychotropic medication allowed in association to the treatment was prazepam (up to 40 mg/day). Patients gave their written consent to the study. Assessment, using the Montgomery Asberg Depression Rating Scale (MADRS), the HARD diagram, the check list for somatic symptoms and side-effects was carried out before treatment and at the end of weeks 2, 4, 8. Assessment of anxiety using the Hamilton Anxiety Rating Scale (HARS) and of sleep disturbances using a sleep questionnaire was carried out before treatment and at week 4. The 8 items of the sleep questionnaire covers the complaints listed in criteria for insomnia disorders (307.42 DSM III-R). Clinical Global Impression (CGI), Therapeutic Index (TI), Tolerance Global Impression were assessed at end-point. The 2 groups were strictly comparable in respect to the clinical status at base line (diagnosis, history and duration of the depressive illness, MADRS and HARD diagram scores).(ABSTRACT TRUNCATED AT 250 WORDS)

Adolescent↗